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Sezary syndrome (SzS), the leukemic stage of cutaneous T-
cell lymphoma (CTCL), is typically a CD4+ T-celllympho-
proliferative disease characterized by numerous immuno-
logic abnormalities, including decreased T-cell responses to 
antigens and mitogens, decreased natural killer and lympho-
cyte-activated killer cell activities, eosinophilia, and in-
creased levels of immunoglobulins, particularly IgE and IgA. 
Because this constellation of abnormalities is reminiscent of 
the pleiotropic in vitro activities ofIL-4 and IL-5, we exam-
ined the possibility that malignant T cells in SzS may be 
producing increased amounts of IL-4 with a concomitant 
decrease in IL-2 and IFN-y production. Such a cytokine se-
cretion pattern would be similar to that produced by murine 
Th2 cells. 
Serum IL-4 enzyme-linked immunosorbent assay measure-
ments revealed that 33% ofSzS patients (n = 21) had levels 
of IL-4 significantly higher (mean, 7.2 pg/ml; range, 
0-48, P < 0.05) than normal controls (mean, 1.59; range, 
0- 3.1). Although the·majority of tested patients had elevated 
serum IgE, no direct correlation between serum IL-4 levels 
and serum IgE levels was observed. 
Peripheral blood mononuclear cells (PBMe) isolated from 
C utaneous T-cell lymphoma (CTCL) is typically a ma-lignant proliferation of T -helper cells that arises in the skin and ultimately s('reads to the nodes, periph-eral blood, and viscera [1 J. The tumor cells are char-acterized by the expression of the CD4 surface anti-
gen and can be further delineated as T -helper/inducer or 
T-"memory" cells that are positive for the CD29 (4B4) surface 
antigen [2]. In the majority of cases the tumor cells do not express 
3Al (CD7), CD45RA, or CD25 (tac) antigens [2,3) . 
SzS patients and stimulated with phytohemagglutinin (PHA) 
produced significantly higher levels of interleukin (IL)-4 and 
significantly lower levels ofIL-2 and interferon (IFN)-y than 
did PBMC from normal controls (p < 0.02, P < 0.05, and 
p < 0.02, respectively). PBMC from SzS patients in remis-
sion produced IL-4 and IL-2 levels similar to that of the 
normal controls. To determine if IFN-y could inhibit the 
increased IL-4 production by PHA-stimulated PBMe from 
SzS patients, IFN-y was added to culture at 0,24, or 48 h prior 
to the addition ofPHA. Significant decreases in IL-4 produc-
tion were seen only in cultures incubated with IFN-y for 24 
and 48 h prior to the addition of PHA. IL-2 levels were not 
affected by IFN-y incubation. 
The increased IL-4 and decreased IL-2 and IFN-y produc-
tion by PBMC from SzS patients suggests that Sezary cells 
have a cytokine profile similar to murine Th2 cells. More-
over, this cytokine secretion pattern may play an integral role 
in the immunopathogenesis of advanced CTCL. The results 
also suggest that IFN-y may be a useful component in the 
spectrum of therapeutic approaches to SzS. ] Invest D ermatol 
99:90-94,1992 
Although the etiology of CTCL remains obscure, the immuno-
biologic course of events that occurs during disease progression has 
been well characterized [4]. In the early stages of disease, T- and 
B-cell responses of CTCL patients are usually unaltered; however, 
as the disease progresses, numerous immunologic abnormalities are 
observed. These abnormalities include decreased T-cell responses to 
antigens and mitogens, decreased natural killer cell (NK) activity, 
decreased lymphokine-activated killer cell (LAK) activity, eosino-
philia, and increased levels of immunoglobulins IgE and IgA [4). 
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Table I. Comparison of SzS Immune Abnormalities [1] and 
IL-4 In Vitro Activities 
SzS Immune Abnormality 
Depressed Mitogenic Response 
Decreased NK Activity 
Decreased LAK Cell Activity 
Increased Levels of IgE 
Decreased Production of IL-2 
~creased Production of IFN-y 
Similar In Vitro IL-4 Activity 
Martinez et al [38] 
Nagler et al [39] 
Kawakami et al [27] 
Coffman and Carty [40] 
Gaya et al [8] 
Peleman et al [23] 
The role that the malignant T cells directly play in these immune 
alterations is unclear. This study, along with previous reports [5] , 
Indicates that a major difference berween the malignant Th cell and 
normal CD4+ /CD29+ Th cells is the inability of peripheral blood 
mononuclear cells (PBMe) isolated from Sezary syndrome (SzS) 
patients to produce normal levels of IL-2 and IFN-y. Moreover, 
upon comparing the observed in vivo immune defects of th~ SzS 
patients with known in vitro activities of various cytokmes, It ap-
peared that there might be a relationship between the in vivo im-
mu~e defects and an excess production of the cytoki~e IL-4 by t~e 
malIgnant T cells (Table I) . The data presented in this report mdl-
cate that PBMC from patients with SzS do indeed produce elevated 
quantities of IL-4 with a concomitant decrease in IL-2 and IFN-y 
production. This cytokine secretion pattern is reminiscent of that of 
the murine Th2 cell and indicates that SzS may represent a human 
Th2-like proliferative disease. 
MATERIALS AND METHODS 
Patients Patients participating in this study were diagnosed with 
SzS, the leukemic form of cutaneous T -cell lymphoma, as defined 
bbY the presence ofT cells with cerebriform nuclei in the periph~ral 
lood, erythroderma, and lymphadenopathy. Patients from which 
PBMC Were tested for cytokine production were selected at random 
Without prior consideration of serum IL-4 and/or IgE. Samples 
Were also obtained from patients who were originally diagnosed as 
haVing SzS but who were in remission (no circulating Sezary cells or 
skin lesions) following 12 to 24 months of therapy with extracorpo-
real photopheresis. No previously obtained specimens from these 
SzS patients in remission were available for testing. All SzS patients 
Were seronegative for HTLV-l antibodies by enzyme-linked im-
~unosorbent assay (ELISA) and had no apparent secondary infec-
tions or other dermatological diseases. Donations of blood by pa-
tients or normal volunteers in this study conformed to 
IRB-approved protocol and informed consent was obtained. 
. PBMC and Serum Venous blood was collected from normal 
volunteers or patients into heparinized syringes or vacutainer tubes 
~Ithout anticoagulant (Becton-Dickenson, Mountain View, C!".). 
erum Was collected from the vacutainer tube subsequent to clottmg ~~d Was stored at -80 a C until assayed. The heparinized blood was ~lut.ed 1: 2 with PBS, pH 7.2, and layered on a ficoll-hypaque 
.} adient (Lymphoprep, Accurate Chemical Corp:, Westbury, NY). 
he gradient was centrifuged at 800 X g for 30 mm at room temper-
ature and the peripheral blood mononuclear cells (PBMe) band 
collected and washed rwo times in PBS. 
Stimulation of Cells for Cytokine Production PBMC were 
suspended in complete media (CM)/(RPMI 1640, JRH Bio-
SCiences.' Lenexa, KS) supplemented with fetal bovine serum (10% 
[(;, Glbco, Grand Island, NY), penicillin/stre~tomycin (final 
S OU (ml] penicillin, [0.1 mg/ml] streptomycin; Sigma Chemical, 
t. LOUIS, MO), and L-glutamine (final [2mM]; Sigma) at a final 
concentration of 106 cells/ml and 1 ml/well of this cell suspension ~as added to a 24-well polysytrene tissue culture plate (Corning, 
(l~rnlng, NY). Cells were then incubated with or without IFN-y 
£ ~U/ml; Genentech, San Francisco, CA) at 37"C and 5% CO2 S~r L' 2~, or 48 h. Following this incubation, PHA (l,ug/ml; Sigma, 
i . OUIS, MO), anti-CD3 (1: 200 dilution of stock; Becton-Dlck-
nson, Mt. View, CA), or PMA (10 ng/ml; Sigma) and the calcium 
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ionophore, A23187 (10 ng/ml; Sigma) were added to select wells 
and the cells were incubated at 37"C and 5% CO2 for an additional 
24 h. Supernatants from the cultures were then harvested and imme-
diately assayed for cytokine activity. 
Cytokine Assay Cytokines were assayed using colorometric en-
zyme immunoassays (IL-2 and IL-4, R&D Systems, Minneapolis, 
MN; IFN-y, Endogen, Inc., Boston, MA) according to the manufac-
turer's specifications. Briefly, 200 ,ul of freshly harvested superna-
tant was added to an assay wei!. Following a 2-h incubation, the 
sample was removed, the assay plate was washed, and a biotinylated 
polyclonal anti-cytokine antibody was added. After an additional 2 
h incubation, the second antibody was removed, the plate was 
washed, and substrate was added. After 20 min, stop solution con-
sisting of2 N H 2S04 was added and the resulting color product was 
read at 450 nm using an automatic plate reader (Titertek Multiskan 
MCC/340, Flow Laboratories, McLean, VA). Calculated sensitivi-
ties of the IL-4, IL-2, and IFN-y ELISA assays were 1 pg/ml, 50 
pg/ml, and 10 pg/ml, respectively. 
Serum IgE Assessment Serum IgE was determined by 
nephelometry using a commercially available kit (Behring Diag-
nostic, Somerville, NJ). 
Statistics IL-4 data was analyzed using a one-tailed, unpaired 
Student t test. p < 0.05 was considered to be statistically significant. 
Correlation was determined using linear regression. 
RESULTS 
Increased Serum IL-4 in CTCL Patients Fresh or frozen 
serum specimens from CTCL patients or normal controls were 
assessed for IL-4 by ELISA. Serum IL-4 ELISA measurements re-
vealed that 7 of 21 CTCL patients (33%) had levels of IL-4 sig-
nificantly higher (mean, 7.2 pg/ml; range, 0-48; p < 0.05) than 
normal controls (n = 7, mean, 1.59 pg/ml; range, 0-3.1) (Fig 1) . 
Increased Serum IgE in CTCL Patients Because IL-4 has been 
demonstrated to induce secretion ofIgE by B cells, serum specimens 
from CTCL patients were assessed for IgE. Elevated IgE was de-
tected in 6 of 9 (66%) CTCL patients tested (mean, 2090 IU /ml; 
range, 41-10,000) as compared to a normal reference range 
(5.0-180 IU /ml). This increase in IgE in CTCL patients was signif-
icantly higher (p < 0.02) when tested using the one-tailed t test 
with a normal population mean of 180 IU /m!. No significant in-
crease in IgG or IgM was observed in any of the patients; however, 
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Figure 1. Serum IL-4levels ofSzS patients and normal controls. Serum was 
assayed by ELISA with a calculated sensitivity of 1 pg/ ml. Serum from 
normal controls (n = 7) had a mean IL-4 level of 1.6 pg/ml (range = 0.0-
3.1 pg/ml), whereas SzS patients had significantly higher mean IL-4 levels 
of7.2 pg/ml (p < 0.05; range = 0.0-48.0 pg/ml). 
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Table II. Serum IgE Levels in Patients with Elevated IL-4a 
Patient 
2 
3 
4 
5 
6 
7 
8 
Serum IL-4 (pg/ml) 
9.0 
19.0 
21.6 
48.0 
17.1 
4.8 
22.2 
3.0' 
, Serum IL-4 levels 2: 3.0 pg/m!. 
'Normal range for serum IgE is 5-180 IU/m!. 
, Not significantly different from normal controls. 
Serum IgE (IU/ml)! 
411 
114 
ND 
3,561 
8 
3,622 
15 
10,000 
IgA was sligh tly elevated in 3 of 9 (33%) cases tested. Elevated 
serum IL-4 (> 3.0 pg/ml) was detected in four of the six patients 
who had elevated levels oflgE (> 300 IU/ml) (Table II) . However, 
there was not a direct correlation between the levels of increase in 
IL-4 and IgE (r2 = 0.07). 
In Vitro IL-4 Production by Stimulated PBMC PBMC from 
CTCL patients (n = 3) with SzS were stimulated in vitro for 24 h 
with PHA following which the supernatants were harvested and 
assessed for IL-4. A significant increase in IL-4 production 
(106.4 ± 28.5 pg/mL, p < 0.02) was seen as compared to unstimu-
lated PBMC from the same patients (8.1 ± 7.8 pg/ml) (Fig 2). IL-4 
production by stimulated PBMC from SzS patients was also signifi-
cantly greater than that of stimulated PBMC from normal controls 
(n = 4,21.2 ± 8.6 pg/ml, p < 0.05). To help determine if Sezary 
cells directly or indirectly contribute to the increased IL-4 produc-
tion by PBMC subsequent to PHA stimulation, three patients who 
were diagnosed as CTCL patients with SzS in remission were exam-
ined (see Materials and Methods). In all three cases, IL-4 production 
was significantly less than that observed in the patients with active 
SzS (31.7 ± 11.6 pg/ml, p < 0.02) and was comparable to IL-4 
production by PBMC from controls. In addition, there appears to be 
a correlation between the percentage of circulating Sezary cells and 
production of IL-4 following PHA stimulation (Table III). In-
creased IL-4 was also produced when SzS PBMC were stimulated 
with anti-CD3 or PMA and A23187 but at concentrations lower 
than those induced by PHA (data not shown). 
In Vitro IL-2 Production by Stimulated PBMC To deter-
mine if the observed increased IL-4 production by PHA-stimulated 
PBMC from patients with SzS was accompanied by a parallel in-
crease in another T-cell cytokine, IL-2 production by these same 
cel ls was examined. IL-2 production by PHA-stimulated PBMC 
from patients with SzS was significantly decreased (332.7 ± 114.5 
pg/ml, p < 0.02) as compared to IL-2 production by PHA-stimu-
lated PBMC from normal controls (10107.0 ± 3482.0 pg/ml) (Fig 
pg / mL 
IL-4 
Control Active SzS Remission SzS 
Figure 2. IL-4 production by stimulated PBMe. PBMC (1.0 X 106/ml) 
from normal controls (n = 4), patients with active SzS (n = 3), and patients 
with SzS in remission (n = 3) were incubated without (l!i!I) or with ~ PHA 
for 24 h. Culture supernatants were assayed by ELISA. PBMC from patients 
with active SzS produced significantly higher levels of IL-4 than PBMC 
from normal controls (p < 0.05) or from SzS patients in remission (p < 
0.02). Results for patients with SzS are representative of three separate 
experiments over a 6-month period during which no significant variation in 
IL-4 production was observed. 
Table III. 
Patient 
SzS 1 
SzS 2 
SzS 3 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
Correlation Between IL-4 Production and Percent of 
Circulating Sezary Cells 
IL-4 Productiona 
75 ± 5 
115±7 
310 ± 15 
Percent Sezary Cells 
35 
42 
82 
5.3 
6.0 
20.0 
, pg/ml ± SD; 10' PBMe/ml were stimulated with PHA for 24 h prior to assay. 
Results for SzS patients are from three separate experiments over a 6-month period. 
'XIO'/mm'. 
3). In addition, IL-2 production was significantly decreased (p < 
0.05) in SzS patients with active disease as compared to SzS patients 
in remission (3762.33 ± 2210.3 pg/ml; range = 1737-6120). 
In Vitro IFN-y Production by Stimulated PBMC To ascer-
tain whether there was a concomitant decrease in IFN-y production 
by PBMC from Sezary patients who were deficient in IL-2 produc-
tion, supernatants from unstimulated or PHA-stimulated PBMe 
were assayed for the presence of IFN-y. PBMC from normal con-
trols (n = 3) produced a significantly higher level of IFN-y 
(33.8 ± 10.9 pg/ml, p < 0.05) than did PBMC from SzS patients 
(n = 3, 6.0 ± 4.5 pg/ml). No IFN-y production was observed from 
normal PBMC or SzS PBMC without stimulation. 
IFN-y Inhibition ofIL-4 Production To determine if the in-
creased production of IL-4 by PBMC from SzS patients following 
PHA stimulation could be inhibited, IFN-y was added to assay wells 
simultaneously with PHA, or 24 h or 48 h prior to the addition of 
PHA. In assays where IFN-y was added simultaneously with PHA, 
no significant inhibition ofIL-4 production was observed (Fig 4). In 
contrast, incubation with IFN-y for 24 h prior to PHA stimulation 
resulted in an average of a 50% decrease in IL-4 production as 
compared to PHA-stimulated cells that were not pre-exposed to 
IFN-y. Moreover, when IFN-y was added 48 h prior to PHA-sti-
mulation, IL-4 production was completely inhibited. Addition of 
IFN-y also inhibited the minimal IL-4 production by PHA-
stimulated PBMC from normal controls. Cell viability remained at 
more than 90% throughout the assay period. 
DISCUSSION 
Cytokine production by T cells has been demonstrated to be an 
essential cell-signaling event in most immunoregulatory systemS 
including cellular and humoral responses to de novo and recall 
antigens, tumor surveillance, and hematopoiesis. Perturbation of 
the normal pattern of cytokine secretion via over- or under-produc-
tion of a specific cytokine can lead to an alteration of normal immu-
nologic function. The present study indicates that an abnormality of 
IL-4, IL-2, and IFN-y production by T cells has occurred in patientS 
with the Sezary form of CTCL, whereas SzS patients in remission 
had cytokine secretion patterns similar to normal controls. 
The underlying mechanism that is responsible for the malignant 
ng / mL 
IL-2 
15 
10 
o ..jL...£..:.= 
Control Active SzS Remission SzS 
Figure 3. IL-2 production by stimulated PBMC. PBMC (1.0 X 106/ ml) 
from normal controls (n = 4), patients with active SzS (n = 3), and patientS 
with SzS in remission (n = 3) were incubated without (l!i!I) or with (II) pHA 
for 24 h. Culture supernatants were assayed by ELISA. PBMC from patientS 
with active SzS produced significantly less ofIL-2 than PBMe from normal 
controls (p < 0.02) or from patients with SzS in remission (p < 0.05). 
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Figure 4. IFN-y inhibition of IL-4 production. IFN-y (100 U j ml) was 
added to cultures simultaneously w ith PHA (0 h) or 24 or 48 h prior to PHA. 
Percent inhibition is shown in parentheses. Data is representative of three 
separate experiments with three SzS patients. 
proliferation of the CD4+ /CD29+ T cells in SzS patients is un-
known. Recent studies examining the cell growth characteristics ~rom these patients indicate that IL-4 may be a significant cofactor 
. Or mducmg proliferation [6] . This stimulation may be the result of 
I[ncreased IL-4 receptors that are present on PBMC of SzS patients 
7]. Based on in vitro studies by Gaya et al [8]' overproduction of 
}L-4 m.ay also be directly responsible for depressed IL-2 production 
olIowmg mitogen stimulation. Furthermore, because it appears 
t[hat IL-2 is at least partially responsible for the induction ofIL-2Ra 
9 -11], the decreased production of IL-2 by SzS PBMC may ac-
COUIlt for the observation that Sezary cells do not express IL-2Ra 
[[12]. In~ibition ofIFN-y production by IL-4 has also been described 
J.3]. It IS not clear, however, if decreased IFN-y production IS a 
frect result of the effect of IL-4 [13] or an indirect result of effects 
o IL-4 on IL-2 production, as IL-2 is a known inducer ofIFN-y [8]. 
The data presented here suggest that most SzS patients with ele-
Vated IL-4 shou ld also have increased serum IgE; however, there 
las a lack of direct correlation between serum IL-4 and serum IgE 
evels. There are several possibilities to explain this lack of direct 
C?rrelation. Serum IL-4 levels may not be an accurate indicator of in 
vhvo IL-4 effects because high concentrations of IL-4 may exist in b' e ~Icroenvironment of interaction with B cells. Because in vivo 
Indmg kinetics and catabolism of IL-4 are unclear, the ability to 
~easure increased IgE may not accurately reflect in vivo levels of 
I -4. In addition, in a study using IL-4 secreting human T-cell 
c ~nes, IL-4 secretion did not always correlate with the ability to 
In uce Or enhance Ig synthesis [14] . 
. ~he ~attern of cytokine secretion in SzS, namely, increased IL-4 
pro Uctlon with a parallel decrease in IFN-y and IL-2 production, 
appears to be analogous to the cytokine pattern of the Th2 cell in the 
~ouse. The murine T -helper cell populations originally described 
Y Mosmann et al [15] and designated Th 1 and Th2, were delin-
ea~fd on the basis of distinct patterns of cytokine secretion. Specifi-
Ca y, T-helper cells that produced IL-2, IFN-y, and Iymphotoxin 
Were d . IL 5 eSlgnated Th 1 cells and T helper cells that produced IL-4, 
c - ,and IL-6 were designated Th2 cells. Production of specific 
t Y~kmes by the murine T -helper subpopulations was determined 
nO e mutually exclusive. Although this functional dichotomy does 
hOt appear to predominate in humans, Th 1- and Th2-like clones 
aVe been described [14,16,17] . 
ex I~ a malignant Th2-like cell is present in SzS, it would help 
St p am many aspects of CTCL pathogenesis, because there is a 
IL~ong correlation between the known in vitro biologic effects of 
h 4 and the immunologic defects of SzS patients (Table I). In a~rn~ns, IL-4 has been demonstrated to have pleiotropic biologic 
cI ~I~ on numerous cell types. The effect of IL-4 on B cells in-of~hes Induction of increased HLA-DR expression [18], induction 
ul . e secretion ofIgE without B-cell preactivation [19,20]' up-reg-
[2~110n ofFC~RII (CD23) [18]' and increas.ed expression ofLF~-l 
de . T cells 111 the presence of IL-4 proltferate [22] and exhibit 
ducreased IFN-y production [13 ,23]. IL-4 inhibits monocyte pro-
Whtlon of IL-l [24], TNF [24], and chemotactic factors [25], 
ereas HLA-DR [26] and LFA-l expression is enhanced [25] . The 
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responsiveness of NK and LAK cells to IL-2 is significantly dimin-
ished in the presence of IL-4 [27]. 
It should be noted, however, that other biologic response modifi-
ers have in vitro activities that overlap with IL-4 and may be respon-
sible for some of the immunologic deficiencies seen in SzS patients. 
One possible candidate for some of the immunodeficiencies seen in 
SzS patients, such as deficient NK cell activity, is TGF-fJ [28] . How-
ever, supernatants collected after a 24-h incubation ofPBMC from 
five SzS patients in serum-free media failed to reveal the presence of 
measurable levels of TGF-fJ (data not shown). 
In addition to the immunologic abnormalities observed in SzS 
patients that may be related to the activities ofIL-4, eosinophilia and 
increased IgA levels often occur in SzS ~atients. Because these are 
known in vitro effects of IL-5 [29 - 31 J, it will be important to 
investigate the production of IL-5 by PBMC from SzS patients . 
These investigations will also help clarify the similarities between 
PBMC from SzS patients and the murine Th2 cell. 
The observation that the cytokine-secretion pattern by PBMC 
from three patients with SzS in remission was not significantly 
different from that of normal controls suggests that a correlation 
may exist between the stage of the disease and aberrant cytokine 
production. This apparent correlation is further strengthened by the 
direct linear relationship between the percentage of Sezary cells in 
the peripheral blood of the study patients and the in vitro produc-
tion of IL-4 by the patients' PBMC (Table III) . Although this evi-
dence is indirect and will require examination of patients at different 
stages of disease as well as testing of enriched populations of Sezary 
cells, these studies appear to indicate a mechanism by which the 
malignant Sezary cell may cause a perturbation in normal immune 
function. In this regard, several recent studies have shown that IL-4 
antagonizes the biologic activity and production ofIFN -y [8 ,13,23] 
and IL-2 [8] indicating one possible mechanism by which IL-4 is 
responsible for the immunologic aberrations observed in SzS pa-
tients. Interestingly, however, IFN -y has been shown to antagonize 
the biologic activity of IL-4 and can even inhibit the growth of 
murine Th2 cells [32,33]. One implication of this observation is 
that in the initial stages of CTCL when the density of infiltrating 
malignant heiperTcells is low, IL-4 and IFN-ymay beimmunoreg-
ulatory, counteracting a portion, but not all , of each other's activity . 
This scenario closely matches that seen in the clinical presentation 
of mycosis fungoides (MF). T cells in MF show a marked epidermo-
tropism. The underlying mechanism for this epidermotropism is 
unclear; however, it has recently been suggested that it is the result 
of the presence of a chemoattractant agent such as IL-8 or IL-l 
[34,35] . Once in the epidermis, the T cells can bind via LFA-l to 
keratinocytes that express a high level of ICAM-l [5], presumably 
induced by IFN-y produced by reactive cells. As the malignant 
T-helper cell population continues to ~expand, increased levels of 
IL-4 would be produced. Eventually, this increased IL-4 production 
could completely counteract the biologic activity and production of 
IFN-y with the resulting loss of ICAM-l expression on keratino-
cytes, and, on a larger scale, the abrogation of immunoregulation in 
the epidermal microenvironment. Such a loss would cause increased 
proliferation of malignant T-helper cells and decreased binding of 
these T cells to keratinocytes due to the loss ofICAM-l, resulting in 
a change from epidermotropism to nonepidermotropis111. One 
well-described indicator of disease progression in CTCL patients is 
such a change from an epidermotropic .1'hase to a nonepidermotro-
pic phase. Furthermore, Nicko loff et ailS] have reported that kerati-
nocytes from Sezary patients, in contrast to keratinocytes from MF 
patients, do not express ICAM-l. However, when keratinocytes 
from these patients were stimulated in vitro with IFN-y, ICAM-l 
expression was detected. Thus, when removed from the in vivo 
environment of the malignant T cell , the keratinocytes could once 
again express ICAM-l normally in response to IFN-y. This furth er 
suggests that the malignant T-cell inhibits ICAM-l expression, 
possibly via the production ofIL-4. In addition, if the initial epider-
motropism is the result of a chemoattractant such as IL-8 or IL-l , 
this activity could also be curtailed because IL-4 can inhibit the 
production of both IL-l and IL-8 [25,36] . 
Because this study demonstrates that IFN-y effectively inhibits 
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the production of IL-4 by PBMC from SzS patients, the use of 
IFN-y to modulate immune function may offer therapeutic benefits 
to patients with SzS. A recent clinical trial that examined the use of 
rlFN-y in the treatment of all stages of CTCL indicated that 31 % of 
the patients experienced a partial response and an additional 38% 
had mixed or minor responses as assessed by regression of skin 
lesions, adenopathy, and peripheral blood involvement [37). Al-
though no complete responses were observed, the results of this 
clinical trial and the data presented here indicate that IFN-y, in 
combination with other therapies, may be effective in treating pa-
tients with SzS. · 
We wish to thank Drs. Lallrellce Walsh alld Margaret B oufal f or their assistatlCe 
with E LISA assays atld Dr. Scott Koenigfor testing supernatant TGF-fllevels. 
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